Use of treponemal screening assay strength of signal to avoid unnecessary confirmatory testing

Gregory J. Berry, Michael J. Loeffelholz

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Our reverse syphilis testing algorithm consists of a treponemal IgG multiplex flow immunoassay (MFI) followed by both rapid plasma reagin titer and the Treponema pallidum particle agglutination (TPPA) test on specimenswith a reactive MFI result.We report here the impact of a modified reverse algorithm, in which the strength of signal of the MFI is used to avoid unnecessary TPPA testing. Methods: The Bioplex syphilis IgGMFI was used as the syphilis screening assay, and specimens with equivocal (antibody index 0.9 or 1.0), or reactive (antibody index ≥ 1.1) results were further tested by rapid plasma reagin titer and TPPA test. We performed a retrospective, descriptive analysis of all specimens received for syphilis screening between January and May of 2014. A cost analysis was performed, taking into account labor and reagent expenses. Results: In our diverse patient population consisting of high-risk incarcerated persons, low-risk obstetrical/gynecological patients and high-risk miscellaneous clinic and inpatients, 430 (65%) of 665MFI-positive specimens had antibody indices of 8 or greater. Greater than 99% of these specimens were reactive by the TPPA test. Avoiding TPPA testing of specimens with an MFI antibody index ≥8 would save over US $4800 annually in laboratory costs. Conclusions: The TPPA testing is unnecessary on specimens with MFI antibody indices ≥8. This would substantially reduce the TPPA testing volume and also reduce laboratory expenses.

Original languageEnglish (US)
Pages (from-to)737-740
Number of pages4
JournalSexually Transmitted Diseases
Volume43
Issue number12
DOIs
StatePublished - Nov 15 2016

Fingerprint

Treponema pallidum
Immunoassay
Agglutination
Syphilis
Agglutination Tests
Reagins
Antibodies
Costs and Cost Analysis
Inpatients
Immunoglobulin G
Population

ASJC Scopus subject areas

  • Dermatology
  • Public Health, Environmental and Occupational Health
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Use of treponemal screening assay strength of signal to avoid unnecessary confirmatory testing. / Berry, Gregory J.; Loeffelholz, Michael J.

In: Sexually Transmitted Diseases, Vol. 43, No. 12, 15.11.2016, p. 737-740.

Research output: Contribution to journalArticle

Berry, Gregory J. ; Loeffelholz, Michael J. / Use of treponemal screening assay strength of signal to avoid unnecessary confirmatory testing. In: Sexually Transmitted Diseases. 2016 ; Vol. 43, No. 12. pp. 737-740.
@article{a80d5af9e797459cade7bd91116ca401,
title = "Use of treponemal screening assay strength of signal to avoid unnecessary confirmatory testing",
abstract = "Background: Our reverse syphilis testing algorithm consists of a treponemal IgG multiplex flow immunoassay (MFI) followed by both rapid plasma reagin titer and the Treponema pallidum particle agglutination (TPPA) test on specimenswith a reactive MFI result.We report here the impact of a modified reverse algorithm, in which the strength of signal of the MFI is used to avoid unnecessary TPPA testing. Methods: The Bioplex syphilis IgGMFI was used as the syphilis screening assay, and specimens with equivocal (antibody index 0.9 or 1.0), or reactive (antibody index ≥ 1.1) results were further tested by rapid plasma reagin titer and TPPA test. We performed a retrospective, descriptive analysis of all specimens received for syphilis screening between January and May of 2014. A cost analysis was performed, taking into account labor and reagent expenses. Results: In our diverse patient population consisting of high-risk incarcerated persons, low-risk obstetrical/gynecological patients and high-risk miscellaneous clinic and inpatients, 430 (65{\%}) of 665MFI-positive specimens had antibody indices of 8 or greater. Greater than 99{\%} of these specimens were reactive by the TPPA test. Avoiding TPPA testing of specimens with an MFI antibody index ≥8 would save over US $4800 annually in laboratory costs. Conclusions: The TPPA testing is unnecessary on specimens with MFI antibody indices ≥8. This would substantially reduce the TPPA testing volume and also reduce laboratory expenses.",
author = "Berry, {Gregory J.} and Loeffelholz, {Michael J.}",
year = "2016",
month = "11",
day = "15",
doi = "10.1097/OLQ.0000000000000524",
language = "English (US)",
volume = "43",
pages = "737--740",
journal = "Sexually Transmitted Diseases",
issn = "0148-5717",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Use of treponemal screening assay strength of signal to avoid unnecessary confirmatory testing

AU - Berry, Gregory J.

AU - Loeffelholz, Michael J.

PY - 2016/11/15

Y1 - 2016/11/15

N2 - Background: Our reverse syphilis testing algorithm consists of a treponemal IgG multiplex flow immunoassay (MFI) followed by both rapid plasma reagin titer and the Treponema pallidum particle agglutination (TPPA) test on specimenswith a reactive MFI result.We report here the impact of a modified reverse algorithm, in which the strength of signal of the MFI is used to avoid unnecessary TPPA testing. Methods: The Bioplex syphilis IgGMFI was used as the syphilis screening assay, and specimens with equivocal (antibody index 0.9 or 1.0), or reactive (antibody index ≥ 1.1) results were further tested by rapid plasma reagin titer and TPPA test. We performed a retrospective, descriptive analysis of all specimens received for syphilis screening between January and May of 2014. A cost analysis was performed, taking into account labor and reagent expenses. Results: In our diverse patient population consisting of high-risk incarcerated persons, low-risk obstetrical/gynecological patients and high-risk miscellaneous clinic and inpatients, 430 (65%) of 665MFI-positive specimens had antibody indices of 8 or greater. Greater than 99% of these specimens were reactive by the TPPA test. Avoiding TPPA testing of specimens with an MFI antibody index ≥8 would save over US $4800 annually in laboratory costs. Conclusions: The TPPA testing is unnecessary on specimens with MFI antibody indices ≥8. This would substantially reduce the TPPA testing volume and also reduce laboratory expenses.

AB - Background: Our reverse syphilis testing algorithm consists of a treponemal IgG multiplex flow immunoassay (MFI) followed by both rapid plasma reagin titer and the Treponema pallidum particle agglutination (TPPA) test on specimenswith a reactive MFI result.We report here the impact of a modified reverse algorithm, in which the strength of signal of the MFI is used to avoid unnecessary TPPA testing. Methods: The Bioplex syphilis IgGMFI was used as the syphilis screening assay, and specimens with equivocal (antibody index 0.9 or 1.0), or reactive (antibody index ≥ 1.1) results were further tested by rapid plasma reagin titer and TPPA test. We performed a retrospective, descriptive analysis of all specimens received for syphilis screening between January and May of 2014. A cost analysis was performed, taking into account labor and reagent expenses. Results: In our diverse patient population consisting of high-risk incarcerated persons, low-risk obstetrical/gynecological patients and high-risk miscellaneous clinic and inpatients, 430 (65%) of 665MFI-positive specimens had antibody indices of 8 or greater. Greater than 99% of these specimens were reactive by the TPPA test. Avoiding TPPA testing of specimens with an MFI antibody index ≥8 would save over US $4800 annually in laboratory costs. Conclusions: The TPPA testing is unnecessary on specimens with MFI antibody indices ≥8. This would substantially reduce the TPPA testing volume and also reduce laboratory expenses.

UR - http://www.scopus.com/inward/record.url?scp=84992144160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992144160&partnerID=8YFLogxK

U2 - 10.1097/OLQ.0000000000000524

DO - 10.1097/OLQ.0000000000000524

M3 - Article

C2 - 27835625

AN - SCOPUS:84992144160

VL - 43

SP - 737

EP - 740

JO - Sexually Transmitted Diseases

JF - Sexually Transmitted Diseases

SN - 0148-5717

IS - 12

ER -